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The development of breast cancer control strategies in women at high genetic risk of breast cancer is an important issue. The
likely beneﬁt of chemopreventive approaches is of particular interest. Tamoxifen tends to be more effective in both
prevention and treatment of oestrogen receptor positive tumours than oestrogen receptor negative. In this study, we combine
the oestrogen-receptor speciﬁc effects of tamoxifen from randomized preventive or therapeutic trials with the oestrogen
receptor status of tumours in BRCA1 and BRCA2 mutation positive women from published tumour surveys to obtain
estimates of the likely effect of tamoxifen administration in mutation carriers. We used a simple two-stage procedure to
estimate the beneﬁt as a weighted average of the effect on oestrogen receptor positive tumours and oestrogen receptor
negative, and using a more complex hierarchical modelling approach. Using the simple procedure and deriving the estimates of
beneﬁt from both primary prevention and therapeutic trials, we obtain an estimated reduction in risk of breast cancer from
administration of tamoxifen in BRCA1 mutation positive women of 13% (RR=0.87, 95% CI 0.68–1.11). The corresponding
estimated reduction in BRCA2 mutation positive women was 27% (RR=0.73, 95% CI 0.59–0.90). Using the more complex
models gave essentially the same results. Using only the primary prevention trials gave smaller estimates of beneﬁt in BRCA1
carriers but larger estimates in BRCA2, in both cases with wider conﬁdence intervals. The beneﬁt of prophylactic use of
tamoxifen in BRCA1 mutation carriers is likely to be modest, and the effect in BRCA2 mutation carriers somewhat greater.
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In randomized trials, tamoxifen has been shown to be effective in
treatment of oestrogen receptor positive (ER+) tumours but not of
oestrogen receptor negative (ER7), in terms of prevention of
recurrences, new primary tumours and fatality (Early Breast Cancer
Trialists’ Collaborative Group, 1998). One primary prevention trial
in the USA found that tamoxifen substantially reduced incidence of
ER+ tumours but had no such effect on ER7 (Fisher et al, 1998).
In sporadic breast cancer, the majority of tumours are ER positive
(Early Breast Cancer Trialists’ Collaborative Group, 1998), whereas
the opposite is the case in cancers diagnosed in women with high
risk mutations in the BRCA1 and BRCA2 genes (Johannsson et al,
1997; Armes et al, 1999).
In this study we synthesize the results on oestrogen receptor
(ER) status from tumour series in mutation carriers with subgroup
analyses by ER status in primary and secondary prevention trials of
long-term tamoxifen use. From this, we derive an estimate of the
likely preventive beneﬁt of long-term tamoxifen administration in
women with high risk BRCA1 and BRCA2 mutations.
MATERIALS AND METHODS
First, three computerized literature searches augmented with
studies brought to our attention by personal communication were
performed: (1) To ﬁnd surveys of ER status in breast cancer
patients with a high risk mutation in the BRCA1 or BRCA2 gene.
Seventeen such studies were found (Johannsson et al, 1997; Karp et
al, 1997; Tirkkonen et al, 1997; Agnarsson et al, 1998; Eiriksdottir
et al, 1998; Loman et al, 1998; Lynch et al, 1998; Osin et al, 1998;
Robson et al, 1998; Verhoog et al, 1998; Wagner et al, 1998; Armes
et al, 1999; Eisinger et al, 1999; Noguchi et al, 1999; Phillips et al,
1999; Tang et al, 1999; Chang et al, 2001). (2) To ﬁnd randomized
trials of tamoxifen administration for at least 3 years for primary
prevention of breast cancer, with published results stratiﬁed by
ER status. Two such trials were found (Fisher et al, 1998; Veronesi
et al, 1998). One other prevention trial did not publish results by
ER status (Powles et al, 1998). (3) To ﬁnd randomized trials of
tamoxifen administration for at least 3 years in breast cancer
patients for prevention of recurrences or new primary breast
cancers, with published results stratiﬁed by ER status. Five such
studies were found (Delozier et al, 1986; Breast Cancer Trials
Committee, 1987; Falkson et al, 1990; Tormey et al, 1992; Rutqvist
et al, 1996).
Results of each of the above three types of study were ﬁrst
synthesized using random effects meta-analysis methods, details
of which are given by Nixon and Duffy (2002). Results of the trials
were then combined with those of the BRCA1 and BRCA2 tumour
surveys in turn, as follows: let R7 be the percentage reduction
conferred by tamoxifen in ER7 tumours, as observed in the
combined randomized trials. Let R+ be the corresponding reduc-
tion in ER+ tumours. Let p represent the proportion of ER+
tumours estimated from the combined results of the BRCA1
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www.bjcancer.comtumour surveys. Then the percentage reduction in breast cancers to
be expected from administration of tamoxifen to subjects with
these mutations is
R  Rp  Rÿ1 ÿ p
We estimated R+, R- and R twice, ﬁrst using both the primary and
secondary prevention trials, and second using the primary prevention
trials only. We calculated a 95% conﬁdence interval on R using the
formula in Appendix 1. The procedures were then repeated using
the proportion of ER+ tumours from the BRCA2 surveys.
Using the above two-stage estimation method, the 95% conﬁ-
dence interval depends on the assumption of independence of R+
and R7, which is not strictly true and may cause overestimation
or underestimation of the standard error. We therefore also esti-
mated p, R+, R7 and R simultaneously in a hierarchical model
with random effects estimation of trial results and tumour series
results (Nixon and Duffy, 2002), using the Gibbs sampling algo-
rithm for estimation, implemented in the Bayesian computer
package BUGS (Gilks et al, 1994). This yields a 95% credible inter-
val (the Bayesian analogue of a conﬁdence interval) which takes
into account the full uncertainty in all parameters simultaneously
and does not assume independence of R+ and R7.
RESULTS
Table 1 shows the individual and combined results of the tumour
surveys of ER status in BRCA1 mutation carriers. The overall esti-
mate of the proportion of ER+ tumours was 0.16 (95% CI 0.09–
0.23). Table 2 shows the corresponding results for BRCA2 muta-
tion carriers, with an overall estimate of the proportion ER+ of
0.65 (95% CI 0.55–0.75).
Table 3 shows the individual and combined effects of tamoxifen
on incidence of ER+ cancers in the randomized trials. In the
primary prevention trials, there was a signiﬁcant overall reduction
in incidence of 59% (RR=0.41, 95% CI 0.24–0.96). For the
secondary prevention trials, the reduction was signiﬁcant at 36%
(RR=0.64, 95% CI 0.41–0.87). For all trials combined, the reduc-
tion was signiﬁcant, at 37% (RR=0.63, 95% CI 0.43–0.80).
Table 4 shows the results of the trials in terms of prevention of
ER7 tumours. In the primary prevention trials there was a non-
signiﬁcant excess of tumours of 5% (RR=1.05, 95% CI 0.55–
1.86). In the secondary prevention studies, there was a non-signiﬁ-
cant reduction of 10% (RR=0.90, 95% CI 0.63–1.24). For all trials
combined, there was a non-signiﬁcant reduction of 9% (RR=0.91,
95% CI 0.69–1.18).
Table 5 gives the results of combining the ﬁndings of the trials with
those of the tumour surveys with BRCA1 mutation positive, by esti-
mation method and type of studies used. There is no signiﬁcant or
sizeable non-signiﬁcant reduction in incidence estimated from the
primary prevention studies alone. When all trials are combined there
is a modest estimated 13% reduction by both the two stage method
(RR=0.87, 95% CI 0.68–1.11) and the simultaneous estimation
method (RR=0.87, 95% CI 0.68–1.10), with P=0.2 in both cases.
The corresponding estimates for BRCA2 mutation positive
women are given in Table 6. The analyses using all trials both yield
a signiﬁcant 27% reduction. Analyses using only the primary
prevention studies give a greater absolute reduction (36–37%),
which just falls short of statistical signiﬁcance (P=0.09) using the
simultaneous estimation procedure (RR=0.64, 95% CI 0.40–1.08).
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Table 1 Oestrogen receptor (ER) status in surveys of tumours in
BRCA1 positive women, with combined estimate of per cent ER receptor
positive tumours
ER+ ER7 ER
tumours tumours status not
Study (%) (%) known Total
Armes et al, 1999 1 (10) 9 (90) 0 10
Chang et al, 2001 1 (13) 7 (87) 0 8
Eisinger et al, 1999 3 (11) 25 (89) 4 32
Johannsson et al, 1997 3 (8) 35 (92) 2 40
Karp et al, 1997 3 (19) 13 (81) 1 17
Loman et al, 1998 9 (33) 18 (67) 0 27
Lynch et al, 1998 5 (23) 17 (77) 0 22
Noguchi et al, 1999 3 (17) 15 (83) 1 19
Osin et al, 1998 3 (12) 22 (88) 0 25
Phillips et al, 1999 2 (18) 9 (82) 2 13
Tang et al, 1999 2 (50) 2 (50) 1 5
Tirkkonen et al, 1997 0 (0) 19 (100) 2 21
Verhoog et al, 1998 9 (36) 16 (64) 24 49
Wagner et al, 1998 1 (6) 17 (94) 16 34
Combined per cent estimates 16 84
Table 2 Oestrogen receptor (ER) status in surveys of tumours in
BRCA2 positive women, with combined estimate of per cent ER receptor
positive tumours
ER+ ER7 ER
tumours tumours status not
Study (%) (%) known Total
Agnarsson et al, 1998 17 (94) 1 (6) 22 40
Armes et al, 1999 6 (67) 3 (33) 0 9
Eiriksdottir et al, 1998 21 (78) 6 (22) 0 27
Karp et al, 1997 4 (100) 0 (0) 0 4
Loman et al, 1998 10 (71) 4 (29) 0 14
Lynch et al, 1998 5 (38) 8 (62) 0 13
Noguchi et al, 1999 6 (60) 4 (40) 4 14
Osin et al, 1998 6 (40) 9 (60) 0 15
Tirkkonen et al, 1997 6 (40) 9 (60) 0 15
Combined per cent estimates 65 35
Table 3 Preventive effects of tamoxifen from the randomized trials, ER+
tumours
RR
Type of (tamoxifen
Study prevention vs control) 95% CI
Fisher et al, 1998 Primary 0.32 0.22–0.44
Veronesi et al, 1998 Primary 1.48 0.52–3.50
Primary prevention, combined Primary 0.41 0.24–0.96
Tormey et al, 1992 Secondary 0.64 0.39–0.99
Falkson et al, 1990 Secondary 0.68 0.45–0.98
Rutqvist et al, 1996 Secondary 0.82 0.68–0.99
Breast Cancer Trials Committee, 1987 Secondary 0.45 0.29–0.67
Delozier et al, 1986 Secondary 0.41 0.17–0.80
Secondary prevention, combined Secondary 0.64 0.41–0.87
All trials combined Both 0.63 0.43–0.80
Table 4 Preventive effects of tamoxifen from the randomized trials,
ER7 tumours
RR
Type of (tamoxifen
Study prevention vs control) 95% CI
Fisher et al, 1998 Primary 1.26 0.76–1.98
Veronesi et al, 1998 Primary 0.73 0.28–1.57
Primary prevention, combined Primary 1.05 0.55–1.86
Tormey et al, 1992 Secondary 0.95 0.55–1.53
Falkson et al, 1990 Secondary 0.92 0.54–1.45
Rutqvist et al, 1996 Secondary 1.10 0.77–1.54
Breast Cancer Trials Committee, 1987 Secondary 0.78 0.53–1.10
Delozier et al, 1986 Secondary 0.86 0.35–1.78
Secondary prevention, combined Secondary 0.90 0.63–1.24
All trials combined Both 0.91 0.69–1.18
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The above suggests that any preventive beneﬁt of tamoxifen in
women positive for the high risk BRCA1 mutation is likely to be
modest, but that a larger beneﬁt of the order of a 25–35% reduc-
tion in incidence may be conferred in BRCA2 mutation carriers.
This ﬁnding stems from the lesser effect of tamoxifen in prevention
or treatment of ER7 cancers, which are more common in BRCA1
mutation carriers.
The literature on this subject is inconclusive (see for example
Eeles and Powles (2000)). There is some support for a substantial
beneﬁt of tamoxifen in prevention of contralateral tumours in
mutation-positive breast cancer cases, from a retrospective case-
control study (Narod et al, 2000). Simulation studies also suggest
a secondary preventive effect (Schrag et al, 2000). Our results
suggest a modest primary preventive effect, which is stronger in
BRCA2 positive women than in BRCA1 positive. In principle,
however, breast cancer risk in BRCA1 positive women should be
amenable to hormonal manipulation, since it has been shown that
oophorectomy reduces risk in such women (Rebbeck, 2000).
The modest effect, whichweobservedin BRCA1mutation carriers,
approaching statistical signiﬁcance, and the clear beneﬁt of the order
of 25–35% in BRCA2, is for the most part consistent with the litera-
ture.TheexceptiontothisisthestudyofNarodetal(2000).Thiswasa
case–control study comparing tamoxifen history in bilateral breast
cancerpatientswithaBRCA1orBRCA2mutation withthatinunilat-
eral patients, also with a mutation. The authors found a substantial
protective effect of tamoxifen on contralateral disease in BRCA1
carriers, with a reduction in odds of 62%. This is admittedly the
secondary preventive effect, but even so the difference in results is
surprising. Our study has the advantage that the treatment effects
are based on prospective randomized studies, but the disadvantage
ofhavingtomaketheassumptionthattheeffectoftamoxifenischieﬂy
dependentonoestrogenreceptorstatus.Theadvantageofthestudyof
Narodetal(2000)isthatitdirectlylinksbreastcanceroccurrencewith
tamoxifen history in women with BRCA1 andBRCA2 mutations. The
disadvantage is its retrospective and non-randomized design. Since
both studies have positive and negative aspects, it is difﬁcult at this
stage to see which is giving the correct answer.
The major assumption in this work is that the principal deter-
minant of the beneﬁt of tamoxifen is the oestrogen receptor
status of the tumour being treated or prevented, and that mutation
status only affects tamoxifen’s performance via the ER status. The
ﬁrst of these seems to be true on the basis of the experimental
evidence (Tables 3 and 4). The results of the trials are at least
consistent with the second (Tables 3 and 4), but it cannot be veri-
ﬁed or refuted for certain without a randomized trial of tamoxifen
status in mutation positive women or a stratiﬁcation of tumours
diagnosed in existing prevention trials by mutation status. This
would also resolve the question raised by the inconsistency of
our results with those of Narod et al (2000). We understand that
this stratiﬁcation is under way in the NSABP-P1 study. In the
Italian prevention trial (Veronesi et al, 1998), some work in
preparation suggests that tamoxifen is effective in preventing
hormone-dependent cancers, as judged by the presence of risk
factors such as low parity and late age at ﬁrst birth, and is not
effective in prevention of non-hormone-dependent cancers, as
judged by absence of reproductive risk factors but presence of a
family history of breast cancer (P Boyle, personal communication).
In the above, we attempted to obtain the preventive effects by ER
status directly from the primary research. For secondary prevention,
we could have simply used the effects of 5 years’ tamoxifen treatment
from the Early Breast Cancer Trialists’ Collaborative Group (1998).
This gave a secondary preventive relative risk of 0.50 for ER+
tumours and 0.94 for ER7. Using these to give the combined esti-
mated beneﬁt from both primary and secondary prevention studies
we would have obtained an estimated reduction of 13% (RR=0.87,
95% CI 0.70–1.08) in BRCA1 positive women and 35% (RR=0.65,
95% CI 0.55–0.76) in BRCA2 positive women. These are similar to
the results in Tables 5 and 6.
The ﬁndings of this work have several implications for future
work. Firstly, if studies are set up to determine the preventive effect
of hormonal agents in women at high genetic or familial risk, rela-
tively modest effects should be postulated in the study size
calculations. Secondly, the preventive effect suggested by our work
in BRCA1 positive women is not substantial and the subjects
would still have a considerable residual absolute risk. For these
women, it may be more proﬁtable to explore non-hormonal
prevention strategies. Finally, in recruitment of high risk women
for hormonal chemoprevention trials, it might be prudent to use
risk criteria based on hormonal rather than familial factors.
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APPENDIX 1
Approximate conﬁdence interval for the two-stage method
The square of the standard error of R is the variance of R, denoted V(R).
VR VRp  Rÿ1 ÿ p  VRpVRÿ1 ÿ p
2CRp;Rÿ1 ÿ p
where C represents the covariance. Noting that V(p) =V(1-p) and assuming
R+,R 7 and p are independent, the above can be estimated as
VR R2
Vpp2VRVpVRR2
ÿVpp2VRÿ
VpVRÿÿ2RRÿVp
Using the delta method we can approximate the standard error of the loga-
rithm of the relative risk R as
s 

VR
p
R
We then calculate the conﬁdence interval on the log relative risk and
retransform to the linear scale in the usual way.
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